Gilead SciencesGILD
GILD
About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees: 17,600
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 275 | Existing positions closed: 110
79% more funds holding in top 10
Funds holding in top 10: 28 [Q4 2024] → 50 (+22) [Q1 2025]
18% more capital invested
Capital invested by funds: $98.3B [Q4 2024] → $116B (+$18B) [Q1 2025]
6% more funds holding
Funds holding: 1,852 [Q4 2024] → 1,966 (+114) [Q1 2025]
0% more call options, than puts
Call options by funds: $1.2B | Put options by funds: $1.19B
1.79% less ownership
Funds ownership: 85.16% [Q4 2024] → 83.37% (-1.79%) [Q1 2025]
17% less repeat investments, than reductions
Existing positions increased: 672 | Existing positions reduced: 806
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$117
6%
upside
Avg. target
$125
14%
upside
High target
$135
23%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Mizuho Salim Syed | 6%upside $117 | Outperform Maintained | 5 May 2025 |
Oppenheimer Hartaj Singh | 14%upside $125 | Outperform Maintained | 25 Apr 2025 |
Morgan Stanley Matthew Harrison | 23%upside $135 | Overweight Maintained | 25 Apr 2025 |
Cantor Fitzgerald Carter Gould | 14%upside $125 | Overweight Assumed | 22 Apr 2025 |
BMO Capital Evan Seigerman | 9%upside $120 | Outperform Maintained | 17 Apr 2025 |
Financial journalist opinion
Based on 38 articles about GILD published over the past 30 days
Neutral
Accesswire
1 day ago
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD)
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ:GILD). Investors who purchased Gilead securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GILD.
Neutral
Accesswire
1 day ago
ATTENTION GILD Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
Neutral
Accesswire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
2 days ago
ATTENTION GILD Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ:GILD). Investors who purchased Gilead securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GILD.
Positive
Zacks Investment Research
2 days ago
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Neutral
Accesswire
3 days ago
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD)
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
Neutral
Accesswire
3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Negative
Zacks Investment Research
3 days ago
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
Charts implemented using Lightweight Charts™